Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors

This study has been terminated.
(Accrual Goal Met)
Sponsor:
Collaborator:
Indiana University
Information provided by:
Indiana University
ClinicalTrials.gov Identifier:
NCT00198172
First received: September 8, 2005
Last updated: May 30, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2007
  Estimated Primary Completion Date: No date given